Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab (150 mg) in Pre-filled Syringe, With or Without Loading Regimen, to Demonstrate Efficacy, Safety and Tolerability up to 2 Years in Patients With Active Psoriatic Arthritis (FUTURE 4)

Next Previous
Trial Profile

A Phase III, Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab (150 mg) in Pre-filled Syringe, With or Without Loading Regimen, to Demonstrate Efficacy, Safety and Tolerability up to 2 Years in Patients With Active Psoriatic Arthritis (FUTURE 4)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 29 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Secukinumab (Primary)
  • Indications Plaque psoriasis; Psoriatic arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms FUTURE 4
  • Sponsors Novartis Pharmaceuticals

    • Most Recent Events

    • 14 Nov 2022 Results of post hoc (n=2504) pooled analysis from the FUTURE 2, 3, 4, 5 and MAXIMISE studies investigated the impact of different levels of HU, and history of gout/uric acid lowering therapy (ULT) on pts with PsA in terms of demographics, clinical characteristics, comorbidities, and clinical response to secukinumab over 1 year, presented at the ACR Convergence 2022.
    • 04 Jun 2022 Results of post hoc analysis included pooled data from PsA pts enrolled in the FUTURE 2-5 and MAXIMISE phase, evaluating the impact of HU on PsA in terms of clinical presentation, severity, comorbidities, and response to secukinumab (SEC) over 1-year, presented at the 23rd Annual Congress of the European League Against Rheumatism
    • 09 Nov 2021 Results of pooled post-hoc analysis assessing efficacy of secukinumab in patients with oligoarticular PsA by using data from five phase III studies presented at the ACR Convergence 2021
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top